D. Boral Capital Initiates Coverage on Turn Therapeutics (NASDAQ:TTRX)

D. Boral Capital assumed coverage on shares of Turn Therapeutics (NASDAQ:TTRX) in a report released on Monday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. D. Boral Capital’s target price indicates a potential upside of 115.63% from the company’s current price.

Turn Therapeutics Price Performance

TTRX opened at $3.71 on Monday. The firm’s 50 day moving average is $3.57. Turn Therapeutics has a twelve month low of $2.57 and a twelve month high of $26.50.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Thursday, November 13th. The company reported ($0.07) EPS for the quarter.

Insiders Place Their Bets

In other news, Director Arthur F. Golden bought 9,868 shares of Turn Therapeutics stock in a transaction that occurred on Monday, November 24th. The stock was bought at an average cost of $3.44 per share, with a total value of $33,945.92. Following the acquisition, the director owned 60,602 shares of the company’s stock, valued at $208,470.88. The trade was a 19.45% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Abraham Chesed bought 14,286 shares of the stock in a transaction that occurred on Thursday, October 23rd. The shares were purchased at an average price of $4.60 per share, for a total transaction of $65,715.60. Following the purchase, the insider owned 1,447,268 shares in the company, valued at $6,657,432.80. This represents a 1.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have purchased 52,136 shares of company stock valued at $183,463.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.